Ann Thorac Surg 2005;79:1081-1089
© 2005 The Society of Thoracic Surgeons
Review
Role of Angiotensin-Converting Enzyme Inhibitors in the Coronary Artery Bypass Patient
Harold L. Lazar, MDa,b,*
a Department of Cardiothoracic Surgery, Boston University School of Medicine, Boston, Massachussetts
b Boston Medical Center, Boston, Massachussetts
* Address reprint requests to Dr Lazar, Department of Cardiothoracic Surgery, Boston Medical Center, 88 E Newton St, B402, Boston, MA 02118 (E-mail: harold.lazar{at}bmc.org).
Angiotensin-converting enzyme inhibitors have been shown to prolong survival and decrease infarct size in patients after acute coronary syndromes. Now there is evidence to suggest that angiotensin-converting enzyme inhibition is beneficial in coronary artery bypass patients. This review will summarize the beneficial effects of angiotensin-converting enzyme inhibition in patients with ischemic heart disease and provide evidence to show that the routine use of angiotensin-converting enzyme inhibition in coronary artery bypass patients can improve clinical outcomes.
Copyright © 2005 by The Society of Thoracic Surgeons.